Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

Majeti, Ravindra

doi:10.1038/onc.2010.511

Cited by 152 publications

(131 citation statements)

References 68 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Although a large number of surface antigens are widely expressed by AML cells, variable expression on leukemic stem cells, hematopoietic stem cells, and other normal tissues limits their utility as CAR targets for all but a few. 6,8,37 Indeed, no widely expressed tumor-specific AML antigen has been described. Among lineage-specific antigens, CD33 has been validated as an AML target by the clinical efficacy of gemtuzumab ozogamicin.…”

Section: Discussionmentioning

confidence: 99%

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

et al. 2014

View full text Add to dashboard Cite

“…Therefore, casein exhibits antileukaemic properties in vitro and in vivo, which is in contrast to the antibody gemtuzumab ozogamicin, which efficiently eliminates leukaemia CD33 + cells in vitro but does not improve the survival of leukaemic individuals (18).…”

Section: Discussionmentioning

confidence: 99%

Casein induces the proliferation of bone marrow mononuclear cells, apoptosis of WEHI-3 leukaemic cells and increased survival in a leukaemia mouse model

et al. 2012

View full text Add to dashboard Cite

“…In some cases, these cells have been shown to express markers such as CLL-1, CD123, CD44, CD47 and CD96, and may also show many immunophenotypic aberrancies commonly seen in AML MRD. [47][48][49][50] CD38 − population in initial and relapse BM specimens found that the initial blast population contained several subsets of blasts with heterogeneous mutational profiles. 3 In 5/6 patients who relapsed, the mutational profile of the blast population was similar to a minor, previously undetected subset of blasts in the initial specimen.…”

Section: Future Directionsmentioning

confidence: 99%

“…51 Studies using xenotransplantation models have shown that monoclonal antibodies directed against CD44, CD123 and CD47 may be useful for the eradication of leukemic stem cells. 49 Thus, MFC may be useful in identification of this potential source of MRD and may help to characterize the expression of potential therapeutic targets to eliminate it.…”

Section: Future Directionsmentioning

confidence: 99%

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

Jaso

Wang

Jorgensen

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Current chemotherapeutic regimens achieve CR in a large percentage of patients with AML. However, relapse after CR remains a significant problem. The presence of leukemic cells at levels too low to be detected by conventional microscopy, termed minimal residual disease (MRD), has been associated with an increased risk of relapse and shortened survival. Detection of MRD requires the use of highly sensitive ancillary techniques. Multi-color flow cytometric immunophenotyping is a sensitive method for quick and accurate detection of MRD. Use of this method in patient management may result in lower rates of relapse and improved survival, and is an effective means of assessing novel therapeutic agents. This method can be used in the vast majority of patients with AML, regardless of the immunophenotypic, cytogenetic and molecular genetic abnormalities present. Unfortunately, conflicting data regarding optimum methods of measurement and reporting, as well as the expertize required to interpret results have limited broad application of this technique. We provide a broad overview of this technique, including its advantages and limitations, and discuss the methods employed at our institution. We also review several possible areas of future investigation. INTRODUCTION AML is characterized by clonal expansion of myeloid precursors in the BM, peripheral blood and/or extramedullary tissues. 1 Current treatment regimens achieve CR in the majority of adult patients; however, approximately 65% of patients develop relapsed disease. 2,3 Thus, there is a need to effectively identify which patients are at most risk for impending relapse. Low levels of leukemic cells, termed minimal residual disease (MRD), have been shown to correlate with an increased risk of relapse and shortened survival believed to be a major cause of relapse. 4 These cells are present at levels below the sensitivity of conventional microscopic examination and as such, their detection requires the use of sensitive ancillary techniques. Detection of MRD by multi-color flow cytometric immunophenotyping (MFC) has been shown to be useful in the detection and characterization of MRD. However, several important concepts must be understood in order to ensure optimal application of this technique in both the clinical and research settings so that the information provided can be translated into better patient outcomes.

show abstract

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

Cited by 152 publications

References 68 publications

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

Casein induces the proliferation of bone marrow mononuclear cells, apoptosis of WEHI-3 leukaemic cells and increased survival in a leukaemia mouse model

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

Contact Info

Product

Resources

About